<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424384</url>
  </required_header>
  <id_info>
    <org_study_id>105012</org_study_id>
    <nct_id>NCT01424384</nct_id>
  </id_info>
  <brief_title>Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic</brief_title>
  <official_title>Emotional Processing in Healthy Male Volunteers Treated With GSK424887. A Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a phase I, single centre, randomised, double blind, double-dummy, placebo
      controlled, parallel group single-dose study in healthy volunteers. The purpose of this study
      is to assess the effect of a single-dose administration of GSK424887, a potent, selective
      competitive antagonist of the human Neurokinin 1 (NK1) receptor and a potent inhibitor of the
      human serotonin transporter (SERT), at the maximum dosage of 100 mg versus placebo and versus
      citalopram (20 mg) on emotional processing in healthy male volunteers. Pharmacokinetics and
      safety following oral administration of GSK424887 will be also evaluated. An Emotional Test
      Battery (ETB) previously used to characterise the effects of antidepressants on positive and
      negative emotion processing in Healthy Volunteers and patients will be used. We hypothesise
      that GSK424887 will modulate emotional information processing acutely. We anticipate that
      these effects may be manifest at sub-effective levels of NK1 and SERT receptor occupancy,
      thus providing pharmacodynamic evidence of the synergistic interaction of the two mechanisms
      in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2008</start_date>
  <completion_date type="Actual">April 30, 2009</completion_date>
  <primary_completion_date type="Actual">April 30, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple emotional and psychometric battery of tests</measure>
    <time_frame>&lt; 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events, laboratory values, vital signs, ECGs</measure>
    <time_frame>&lt; 1 day</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Depressive Disorder and Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed comparitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Medicinal Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK424887</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo To Match Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Neurophysiological testing.</description>
    <arm_group_label>Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK424887</intervention_name>
    <description>Neurophysiological testing</description>
    <arm_group_label>Investigational Medicinal Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plactebo To Match</intervention_name>
    <description>Neurophysiological testing</description>
    <arm_group_label>Placebo To Match Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males with no neurological, or history of psychiatric illness

          2. Aged between 18 and 45 years

          3. Agree to use contraception

          4. BMI range of 18 to 33 kg/m²

          5. Fluent English speakers

          6. Non smoker or light smoker

        Exclusion Criteria:

          1. Positive pre-study drug/alcohol screen or regular alcohol consumption

          2. Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result
             within 3 months of screening

          3. On prescription or non prescription drug

          4. Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day

          5. Consumption of large amounts of caffeinated drinks

          6. Significant hearing impairment

          7. Previous experience of the emotional test battery experimental procedures
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/105012?search=study&amp;study_ids=105012#rs</url>
    <description>Results for study 105012 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Harmer CJ, Dawson GR, Dourish CT, Favaron E, Parsons E, Fiore M, Zucchetto M, Bifone A, Poggesi I, Fernandes S, Alexander RC, Goodwin GM. Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans. J Psychopharmacol. 2013 May;27(5):435-43. doi: 10.1177/0269881112472558. Epub 2013 Feb 12.</citation>
    <PMID>23407644</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>Anxiety Disorder</keyword>
  <keyword>neuropsychological tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105012</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

